[ad_1]
Dublin, July 13, 2021 (Global News Service) – “Targeted protein degradation market: Focus on technology platforms and therapeutic drugs: According to the type of protein degradation agent, therapeutic field, route of administration, key contribution technology and key geographic distribution, 2021-2030” Report has been added to ResearchAndMarkets.com provide.
Targeted protein degradation is a revolutionary pharmacological concept that provides viable drug development opportunities and is expected to introduce new paradigms in modern therapeutic interventions. For various reasons, conventional drugs/therapies are limited in their ability to target certain pathologically significant proteins. Currently, medical researchers engaged in the development of interventions based on bifunctional protein degradation agents claim that such upcoming drugs can target biomolecules in the human proteome, which were previously considered non-medicable. The concept of targeted protein degradation revolves around the use of small molecule leaders that can recruit the ubiquitin-proteasome system (UPS) to selectively eliminate target biomolecules.
In other words, protein degradation agents regulate biological pathways by selectively down-regulating them by degrading target proteins; this process has been shown to be robust, more sensitive to drug-resistant targets, and can regulate cell functions that do not depend on enzyme action. In addition, compared with traditional enzyme inhibitors, drugs designed based on this relatively novel concept have been proven to have significant selectivity, high potency, oral bioavailability and differentiated pharmacology. Therefore, this kind of upcoming drugs has aroused great interest in the medical community. In fact, since 2014, a capital investment of US$5 billion has been made in companies engaged in this field of research, which indicates the increasing popularity of targeted protein degradation.
The proteolytic targeting chimera (PROTAC) developed by Hashimoto’s laboratory in 2008 was the first targeted protein degradation agent. Researchers involved in this field continue to work hard and have made significant progress in understanding the physical, chemical and biological properties of such bifunctional molecules. At present, there are several other types of targeted protein degradation agents and molecular glues that have been/are being developed for the treatment of various clinical diseases, including acute myeloid leukemia, Alzheimer’s disease, breast cancer, myelofibrosis, and multiple Myeloma, Parkinson’s disease, prostate cancer, psoriasis, rheumatoid arthritis, and supranuclear palsy. It is worth noting that the research and development work in this field is supported by DNA coding libraries and other computer hit discovery and characterization tools. In the past 4-5 years, the number of new entrants to this market has increased significantly.
In addition, several large pharmaceutical companies are also actively participating in this field, evaluating proprietary therapeutic clues based on protein degrading agents. In the past few years, the market has also witnessed a large number of cooperation activities, and some technology developers have participated in high-value licensing transactions. Although there are no approved drugs/therapeutic products based on protein degradants, the market is expected to witness healthy growth in the next decade.
Among other elements, the report includes:
- A detailed review of the current market pattern of targeted therapeutics based on protein degradation, including the types of protein degradation agents (degronimids, ENDTAC, epichaperome inhibitors, hydrophobic tags, IMiD, LYTAC, molecular glue, PHOTOAC, PROTAC, protein homeostasis regulation Information on agents, SARDs), SERD, SNIPER and specific BET and DUB inhibitors), the development stage (clinical, preclinical and discovery stage) of…
The full story on Benzinga.com
[ad_2]
Source link
